(Reuters) – Catalent (NYSE:) said on Friday it could not submit its annual report to regulators on time because it needs additional time to complete “certain processes”.
The contract drug manufacturer was expected to submit the report on August 29.
The company is awaiting the completion of the $16.5 billion acquisition deal signed in February by Novo Holdings, the investment company that owns a majority stake in Danish drug manufacturer Novo Nordisk (NYSE:).
Catalent expects the deal to be completed by the end of the year.
Catalent is a contractor that carries out filling operations, including the filling and packaging of syringes and injection pens in sterile conditions, including Novo Nordisk’s successful drug Wegovy.
The US Federal Trade Commission asked for more information about the deal in May, after Novo Holdings applied for clearance from the antitrust agency.
The company beat analysts’ expectations for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and produces cell and gene therapies.
